Oncolys BioPharma: Announcements of individual stocks regarding the mass exercise of the 20th subscription rights (including the exercise price adjustment clause and exercise suspension clause) issued through third-party allotment.
Oncolys BioPharma: Announcements of individual stocks: Final analysis results for the C-9 ALS Phase 2a trial of OBP-601 (censavudine, TPN-101).
Oncolys BioPharma: Announcements of individual stocks regarding patent evaluation in OBP-801 ophthalmology field.
Oncolys BioPharma: Announcements of individual stocks regarding responses to inquiries.
Oncolys BioPharma: Announcement of the establishment of a new organization.
Oncolys BioPharma: Patients with esophageal gastric adenocarcinoma refractory to immunotherapy who were first enrolled in the OBP-301 phase 2 clinical trial of pembrolizumab initiated by the investigator responsible physician
Oncolys BioPharma: Notice regarding the commencement of administration of the US Phase 2 clinical trial for second-line treatment of treatment-resistant gastric cancer containing anti-PD-1/PD-L1 antibodies to telomerysin
Oncolys BioPharma: Notice regarding responses to inquiries
Oncolys BioPharma: Notice regarding fast track designation of OBP-601 (censavudine, TPN-101) for progressive supranuclear palsy (PSP)
Oncolys BioPharma: Notice Concerning the Recording of Non-Operating Income and Non-Operating Expenses
Oncolys BioPharma: Unconsolidated financial results for the three months ended 2024/3/31 [Japanese GAAP]
Oncolis Biopharma: Notice regarding responses to inquiries
Oncolys BioPharma: Notice of publication of the log me finance transcript of the business briefing
Oncolis Biopharma: Notice Concerning Mass Exercise of the 19th Stock Acquisition Rights (with Exercise Price Amendment Clauses), Monthly Exercise Status, and Completion of Exercise of Rights
Oncolis Biopharma: Notice regarding resolution results etc. of the Annual General Meeting of Shareholders
Oncolys BioPharma: Matters relating to business plans and growth potential
Oncolys BioPharma: Notice regarding responses to inquiries
Oncolis Biopharma: Announcement of the release of the “Oncolis Introduction Video”
Oncolis Biopharma: Notice Concerning the Monthly Exercise Status of the 19th Stock Acquisition Rights (with Exercise Price Amendment Clauses)
Oncolis Biopharma: Notice Concerning Mass Exercise of the 19th Stock Acquisition Rights (with Exercise Price Amendment Clauses)
No Data